Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.59
WAG's Cash to Debt is ranked higher than
74% of the 557 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. WAG: 0.59 )
WAG' s 10-Year Cash to Debt Range
Min: 0.04   Max: No Debt
Current: 0.59

Equity to Asset 0.55
WAG's Equity to Asset is ranked higher than
85% of the 554 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. WAG: 0.55 )
WAG' s 10-Year Equity to Asset Range
Min: 0.54   Max: 0.63
Current: 0.55

0.54
0.63
Interest Coverage 26.88
WAG's Interest Coverage is ranked higher than
76% of the 424 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.07 vs. WAG: 26.88 )
WAG' s 10-Year Interest Coverage Range
Min: 23.88   Max: 9999.99
Current: 26.88

23.88
9999.99
F-Score: 5
Z-Score: 5.63
M-Score: -2.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 5.49
WAG's Operating margin (%) is ranked higher than
88% of the 559 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.46 vs. WAG: 5.49 )
WAG' s 10-Year Operating margin (%) Range
Min: 4.84   Max: 6.05
Current: 5.49

4.84
6.05
Net-margin (%) 2.53
WAG's Net-margin (%) is ranked higher than
81% of the 559 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.15 vs. WAG: 2.53 )
WAG' s 10-Year Net-margin (%) Range
Min: 2.53   Max: 3.8
Current: 2.53

2.53
3.8
ROE (%) 9.46
WAG's ROE (%) is ranked higher than
76% of the 547 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9.86 vs. WAG: 9.46 )
WAG' s 10-Year ROE (%) Range
Min: 9.68   Max: 20.13
Current: 9.46

9.68
20.13
ROA (%) 5.26
WAG's ROA (%) is ranked higher than
82% of the 561 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.98 vs. WAG: 5.26 )
WAG' s 10-Year ROA (%) Range
Min: 5.32   Max: 11.94
Current: 5.26

5.32
11.94
ROC (Joel Greenblatt) (%) 29.57
WAG's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 560 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 18.41 vs. WAG: 29.57 )
WAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 24.31   Max: 53.07
Current: 29.57

24.31
53.07
Revenue Growth (%) 0.50
WAG's Revenue Growth (%) is ranked higher than
60% of the 493 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.70 vs. WAG: 0.50 )
WAG' s 10-Year Revenue Growth (%) Range
Min: 0.5   Max: 16.5
Current: 0.5

0.5
16.5
EBITDA Growth (%) -1.10
WAG's EBITDA Growth (%) is ranked higher than
67% of the 458 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.00 vs. WAG: -1.10 )
WAG' s 10-Year EBITDA Growth (%) Range
Min: -1.1   Max: 17.9
Current: -1.1

-1.1
17.9
EPS Growth (%) -12.10
WAG's EPS Growth (%) is ranked higher than
62% of the 415 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.20 vs. WAG: -12.10 )
WAG' s 10-Year EPS Growth (%) Range
Min: -12.1   Max: 20
Current: -12.1

-12.1
20
» WAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

WAG Guru Trades in Q4 2013

John Keeley 3,682 sh (New)
Andreas Halvorsen 11,604,944 sh (New)
Steven Cohen 335,584 sh (+357.89%)
RS Investment Management 52,100 sh (+5.68%)
George Soros 515,700 sh (+3.14%)
First Pacific Advisors 2,295,200 sh (+0.29%)
Pioneer Investments 2,325,918 sh (+0.06%)
Steven Romick 2,175,000 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
Chuck Royce Sold Out
Louis Moore Bacon Sold Out
John Rogers Sold Out
Tom Gayner 2,147,450 sh (-0.08%)
Ken Fisher 5,737 sh (-0.31%)
John Buckingham 150,884 sh (-0.95%)
Mario Gabelli 188,750 sh (-1.41%)
Jeremy Grantham 3,555,906 sh (-2.31%)
Jim Simons 1,387,600 sh (-4.42%)
James Barrow 6,972,657 sh (-7.91%)
Vanguard Health Care Fund 10,913,200 sh (-12.46%)
Bill Frels 14,013 sh (-16.53%)
Larry Robbins 5,951,526 sh (-20.04%)
Manning & Napier Advisors, Inc 70,004 sh (-28.29%)
John Hussman 150,000 sh (-49.41%)
Paul Tudor Jones 14,008 sh (-85.99%)
» More
Q1 2014

WAG Guru Trades in Q1 2014

John Griffin 3,435,000 sh (New)
Stanley Druckenmiller 1,240,000 sh (New)
Louis Moore Bacon 244,750 sh (New)
Andreas Halvorsen 24,105,841 sh (+107.72%)
George Soros 850,000 sh (+64.82%)
Paul Tudor Jones 19,946 sh (+42.39%)
RS Investment Management 56,200 sh (+7.87%)
First Pacific Advisors 2,304,500 sh (+0.41%)
Eric Mindich 1,000,000 sh (unchged)
John Keeley 3,682 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Dodge & Cox 6,069 sh (unchged)
Larry Robbins 500,000 sh (unchged)
Jim Simons Sold Out
John Hussman Sold Out
John Buckingham Sold Out
Pioneer Investments 2,316,700 sh (-0.4%)
Tom Gayner 2,135,000 sh (-0.58%)
Manning & Napier Advisors, Inc 69,126 sh (-1.25%)
Vanguard Health Care Fund 10,073,000 sh (-7.7%)
Mario Gabelli 172,950 sh (-8.37%)
Bill Frels 12,663 sh (-9.63%)
Larry Robbins 5,190,926 sh (-12.78%)
Ken Fisher 4,263 sh (-25.69%)
Jeremy Grantham 662,105 sh (-81.38%)
James Barrow 960,997 sh (-86.22%)
Steven Cohen 24,535 sh (-92.69%)
» More
Q2 2014

WAG Guru Trades in Q2 2014

Caxton Associates 70,000 sh (New)
Jean-Marie Eveillard 1,306,571 sh (New)
Lee Ainslie 1,318,963 sh (New)
Daniel Loeb 700,000 sh (New)
John Griffin 6,245,000 sh (+81.8%)
George Soros 1,300,000 sh (+52.94%)
RS Investment Management 66,100 sh (+17.62%)
Ken Fisher 4,754 sh (+11.52%)
First Pacific Advisors 2,314,100 sh (+0.42%)
John Keeley 3,683 sh (+0.03%)
Steven Cohen 150,000 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Larry Robbins 500,000 sh (unchged)
Bill Frels 12,663 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Stanley Druckenmiller 1,240,000 sh (unchged)
Pioneer Investments 2,314,940 sh (-0.08%)
Mario Gabelli 171,700 sh (-0.72%)
Dodge & Cox 5,669 sh (-6.59%)
James Barrow 819,847 sh (-14.69%)
Andreas Halvorsen 20,137,154 sh (-16.46%)
Vanguard Health Care Fund 7,128,300 sh (-29.23%)
Larry Robbins 3,577,926 sh (-31.07%)
Paul Tudor Jones 12,930 sh (-35.17%)
Louis Moore Bacon 54,320 sh (-77.81%)
Manning & Napier Advisors, Inc 14,515 sh (-79%)
Jeremy Grantham 76,100 sh (-88.51%)
» More
Q3 2014

WAG Guru Trades in Q3 2014

John Hussman 150,000 sh (New)
Joel Greenblatt 252,443 sh (New)
Jim Simons 702,200 sh (New)
Paul Tudor Jones 40,650 sh (+214.39%)
Dodge & Cox 12,574 sh (+121.8%)
Mario Gabelli 298,155 sh (+73.65%)
Ken Fisher 7,901 sh (+66.2%)
Vanguard Health Care Fund 8,621,200 sh (+20.94%)
George Soros 1,426,000 sh (+9.69%)
Andreas Halvorsen 20,711,731 sh (+2.85%)
First Pacific Advisors 2,333,600 sh (+0.84%)
Tom Gayner 2,135,000 sh (unchged)
John Keeley 3,683 sh (unchged)
Steven Romick 2,175,000 sh (unchged)
Eric Mindich 1,000,000 sh (unchged)
Jean-Marie Eveillard Sold Out
Caxton Associates Sold Out
Steven Cohen Sold Out
Larry Robbins Sold Out
Lee Ainslie Sold Out
Daniel Loeb Sold Out
Bill Frels 12,595 sh (-0.54%)
John Griffin 4,850,000 sh (-22.34%)
James Barrow 507,617 sh (-38.08%)
Stanley Druckenmiller 648,000 sh (-47.74%)
Louis Moore Bacon 19,650 sh (-63.83%)
Manning & Napier Advisors, Inc 3,869 sh (-73.34%)
RS Investment Management 7,300 sh (-88.96%)
Jeremy Grantham 4,400 sh (-94.22%)
Pioneer Investments 4,209 sh (-99.82%)
» More
» Details

Insider Trades

Latest Guru Trades with WAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2014-09-30 Sold Out 1.4%$59.21 - $73.98 $ 67.814%0
John Griffin 2014-09-30 Reduce -22.34%1.03%$59.21 - $73.98 $ 67.814%4850000
John Hussman 2014-09-30 New Buy0.76%$59.21 - $73.98 $ 67.814%150000
Daniel Loeb 2014-09-30 Sold Out 0.64%$59.21 - $73.98 $ 67.814%0
Jean-Marie Eveillard 2014-09-30 Sold Out 0.23%$59.21 - $73.98 $ 67.814%0
Vanguard Health Care Fund 2014-09-30 Add 20.94%0.23%$59.21 - $73.98 $ 67.814%8621200
Joel Greenblatt 2014-09-30 New Buy0.15%$59.21 - $73.98 $ 67.814%252443
Andreas Halvorsen 2014-09-30 Add 2.85%0.14%$59.21 - $73.98 $ 67.814%20711731
Mario Gabelli 2014-09-30 Add 73.65%0.04%$59.21 - $73.98 $ 67.814%298155
James Barrow 2014-09-30 Reduce -38.08%0.03%$59.21 - $73.98 $ 67.814%507617
Ken Fisher 2014-09-30 Add 66.2%$59.21 - $73.98 $ 67.814%7901
Dodge & Cox 2014-09-30 Add 121.8%$59.21 - $73.98 $ 67.814%12574
John Griffin 2014-06-30 Add 81.8%2.07%$63.4 - $76.08 $ 67.81-3%6245000
Lee Ainslie 2014-06-30 New Buy1.4%$63.4 - $76.08 $ 67.81-3%1318963
Andreas Halvorsen 2014-06-30 Reduce -16.46%1.1%$63.4 - $76.08 $ 67.81-3%20137154
Daniel Loeb 2014-06-30 New Buy0.64%$63.4 - $76.08 $ 67.81-3%700000
Vanguard Health Care Fund 2014-06-30 Reduce -29.23%0.56%$63.4 - $76.08 $ 67.81-3%7128300
George Soros 2014-06-30 Add 52.94%0.25%$63.4 - $76.08 $ 67.81-3%1300000
Jean-Marie Eveillard 2014-06-30 New Buy0.23%$63.4 - $76.08 $ 67.81-3%1306571
Andreas Halvorsen 2014-03-31 Add 107.72%3.47%$55.57 - $69.09 $ 67.818%24105841
John Griffin 2014-03-31 New Buy2.5%$55.57 - $69.09 $ 67.818%3435000
John Hussman 2014-03-31 Sold Out 0.61%$55.57 - $69.09 $ 67.819%0
James Barrow 2014-03-31 Reduce -86.22%0.5%$55.57 - $69.09 $ 67.818%960997
George Soros 2014-03-31 Add 64.82%0.22%$55.57 - $69.09 $ 67.818%850000
Vanguard Health Care Fund 2014-03-31 Reduce -7.7%0.15%$55.57 - $69.09 $ 67.819%10073000
Ken Fisher 2014-03-31 Reduce -25.69%$55.57 - $69.09 $ 67.819%4263
Andreas Halvorsen 2013-12-31 New Buy3.1%$54.86 - $60.59 $ 67.8116%11604944
John Hussman 2013-12-31 Reduce -49.41%0.43%$54.86 - $60.59 $ 67.8116%150000
Vanguard Health Care Fund 2013-12-31 Reduce -12.46%0.29%$54.86 - $60.59 $ 67.8116%10913200
John Rogers 2013-12-31 Sold Out 0.08%$54.86 - $60.59 $ 67.8116%0
John Keeley 2013-12-31 New Buy$54.86 - $60.59 $ 67.8116%3682
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Walgreen Co

Mario Gabelli Comments on Walgreen Co - Nov 21, 2014

Walgreen Co. (0.1%) (WAG - $59.27 - NYSE) is becoming a global pharmacy and drug wholesaler through the pending acquisition of Alliance Boots. The combined companies should garner significant purchasing and operational synergies from their worldwide scale, with a strong presence in emerging markets. Management is also becoming more shareholder friendly, granting two Board seats to an activist investor and committing to return significant amounts of cash to shareholders via dividends and share repurchases. While there are likely to be some bumps in the road during the integration process, we believe the combined company will be an attractive global leader in the industry.

From Mario Gabelli (Trades, Portfolio)’s Asset Fund Q3 2014 Commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Walgreen Co

Mario Gabelli Comments on Walgreen Co
Walgreen Co. (0.1%) (WAG - $59.27 - NYSE) is becoming a global pharmacy and drug wholesaler through the pending acquisition of Alliance Boots. The combined companies should garner significant purchasing and operational synergies from their worldwide scale, with a strong presence in emerging markets. Management is also becoming more shareholder friendly, granting two Board seats to an activist investor and committing to return significant amounts of cash to shareholders via dividends and share repurchases. While there are likely to be some bumps in the road during the integration process, we believe the combined company will be an attractive global leader in the industry. Read more...
Large Insider Buys At These Three Companies
As the sharp selloff continues in the markets, I looked to the Insiders section of the GuruFocus website to see if any company executives are demonstrating faith in their companies by buying more shares. In the last two corrections large amounts of insiders stepped in and bought their stock near the lows. Who else is there to know better about a company’s future prospects than its own executives? Read more...
NEW SITE FEATURE: 10-Year Median Scans
GuruFocus has always delievered the most vast offering of equity research tools available on the market. Last year we introduced the All-In-One Guru Screener. It has been met with immensely positive feedback and has quickly become the go-to scanner for sophisticated investors. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 33.90
WAG's P/E(ttm) is ranked higher than
66% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 23.60 vs. WAG: 33.90 )
WAG' s 10-Year P/E(ttm) Range
Min: 10.2   Max: 35.27
Current: 33.9

10.2
35.27
P/B 3.15
WAG's P/B is ranked higher than
64% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.17 vs. WAG: 3.15 )
WAG' s 10-Year P/B Range
Min: 1.6   Max: 5.58
Current: 3.15

1.6
5.58
P/S 0.86
WAG's P/S is ranked higher than
63% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. WAG: 0.86 )
WAG' s 10-Year P/S Range
Min: 0.36   Max: 1.2
Current: 0.86

0.36
1.2
PFCF 23.44
WAG's PFCF is ranked higher than
83% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 82.07 vs. WAG: 23.44 )
WAG' s 10-Year PFCF Range
Min: 9.86   Max: 368.77
Current: 23.44

9.86
368.77
EV-to-EBIT 15.81
WAG's EV-to-EBIT is ranked higher than
76% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.82 vs. WAG: 15.81 )
WAG' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 19.9
Current: 15.81

6.3
19.9
PEG 8.27
WAG's PEG is ranked higher than
80% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 31.17 vs. WAG: 8.27 )
WAG' s 10-Year PEG Range
Min: 0.5   Max: 6.45
Current: 8.27

0.5
6.45
Shiller P/E 27.26
WAG's Shiller P/E is ranked higher than
83% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 33.54 vs. WAG: 27.26 )
WAG' s 10-Year Shiller P/E Range
Min: 12.07   Max: 42.03
Current: 27.26

12.07
42.03
Current Ratio 1.38
WAG's Current Ratio is ranked higher than
80% of the 559 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.13 vs. WAG: 1.38 )
WAG' s 10-Year Current Ratio Range
Min: 1.23   Max: 1.9
Current: 1.38

1.23
1.9
Quick Ratio 0.69
WAG's Quick Ratio is ranked higher than
74% of the 559 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.63 vs. WAG: 0.69 )
WAG' s 10-Year Quick Ratio Range
Min: 0.3   Max: 0.78
Current: 0.69

0.3
0.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.93
WAG's Dividend Yield is ranked higher than
58% of the 472 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.79 vs. WAG: 1.93 )
WAG' s 10-Year Dividend Yield Range
Min: 0.44   Max: 3.11
Current: 1.93

0.44
3.11
Dividend Payout 0.64
WAG's Dividend Payout is ranked higher than
65% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.61 vs. WAG: 0.64 )
WAG' s 10-Year Dividend Payout Range
Min: 0.14   Max: 0.64
Current: 0.64

0.14
0.64
Dividend growth (3y) 19.60
WAG's Dividend growth (3y) is ranked higher than
93% of the 387 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. WAG: 19.60 )
WAG' s 10-Year Dividend growth (3y) Range
Min: 3.7   Max: 26
Current: 19.6

3.7
26
Yield on cost (5-Year) 5.11
WAG's Yield on cost (5-Year) is ranked higher than
84% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.00 vs. WAG: 5.11 )
WAG' s 10-Year Yield on cost (5-Year) Range
Min: 1.18   Max: 8.37
Current: 5.11

1.18
8.37
Share Buyback Rate -1.40
WAG's Share Buyback Rate is ranked higher than
67% of the 380 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.20 vs. WAG: -1.40 )
WAG' s 10-Year Share Buyback Rate Range
Min: 3.9   Max: -1.4
Current: -1.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.81
WAG's Price/Tangible Book is ranked higher than
70% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.17 vs. WAG: 3.81 )
WAG' s 10-Year Price/Tangible Book Range
Min: 2.21   Max: 7.85
Current: 3.81

2.21
7.85
Price/DCF (Projected) 1.52
WAG's Price/DCF (Projected) is ranked higher than
85% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.57 vs. WAG: 1.52 )
WAG' s 10-Year Price/DCF (Projected) Range
Min: 0.83   Max: 13.11
Current: 1.52

0.83
13.11
Price/Median PS Value 1.32
WAG's Price/Median PS Value is ranked higher than
66% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.13 vs. WAG: 1.32 )
WAG' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 2.43
Current: 1.32

0.6
2.43
Price/Peter Lynch Fair Value 6.19
WAG's Price/Peter Lynch Fair Value is ranked higher than
82% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 9999.00 vs. WAG: 6.19 )
WAG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.8   Max: 5.53
Current: 6.19

0.8
5.53
Price/Graham Number 2.32
WAG's Price/Graham Number is ranked higher than
73% of the 585 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.47 vs. WAG: 2.32 )
WAG' s 10-Year Price/Graham Number Range
Min: 1.09   Max: 3.86
Current: 2.32

1.09
3.86
Earnings Yield (Greenblatt) 6.30
WAG's Earnings Yield (Greenblatt) is ranked higher than
75% of the 549 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.20 vs. WAG: 6.30 )
WAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5   Max: 15.9
Current: 6.3

5
15.9
Forward Rate of Return (Yacktman) 8.96
WAG's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 456 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.07 vs. WAG: 8.96 )
WAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 9.5   Max: 23.8
Current: 8.96

9.5
23.8

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:WGN.Germany, WAG.Mexico
Walgreen Co was incorporated in Illinois on February 15, 1990. The Company together with its subsidiaries operates drug-stores chain in the United States. The Company provides consumer goods and services, pharmacy, and health and wellness services in communities across America. It also offers products and services through drugstores, as well as through mail, telephone, online and mobile application. The Company sells prescription and non-prescription drugs as well as general merchandise, including convenience and fresh foods, household items, personal care, photofinishing and beauty care. Its pharmacy, health and wellness services include retail, specialty, infusion and respiratory services, mail service, convenient care clinics and wellness centers. It also offers specialty pharmacy services that provide customers nationwide access to a variety of medications, services and programs for managing complex and chronic health conditions. The Company offers its customers infusion therapy services including the administration of intravenous (IV) medications for cancer treatments, chronic pain, heart failure, and other infections and disorders. It provides infusion services at home, at the workplace, in a physician's office or online. It also provides clinical services including laboratory monitoring, medication profile review, nutritional assessments and patient and caregiver education. The Company's pharmacy system offers pharmacists access to patient prescription records. As of August 31, 2014, there were approximately 8,309 drugstore and other locations in all 50 states, the District of Columbia, Puerto Rico and U.S. Virgin Islands. The Company's business is subject to federal, state and local laws, regulations, and administrative practices concerning the provision of and payment for health care services.
» More Articles for WAG

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Walgreen Co Nov 21 2014 
Dividend Aristocrats In Focus Part 26 of 54: Walgreens Oct 23 2014 
Will Clinics Boost Walmart's Profitability? Oct 21 2014 
Large Insider Buys At These Three Companies Oct 15 2014 
Why The Diplomat Pharmacy IPO Could Rock The Industry Oct 12 2014 
5 Stocks With Strong Dividend Growth Metrics Oct 07 2014 
Walmart Writing A New Chapter In Retail Business Oct 07 2014 
Three Stocks for a Worry-Free Retirement Oct 06 2014 
Revival Of RadioShack Oct 05 2014 
AmerisourceBergen Is a Center Piece in the Pharma Industry Sep 30 2014 

More From Our Partners
Selecting Core Stocks For My Dividend Growth IRA Nov 21 2014 - SEEKINGALPHA

More From Other Websites
Walgreens Earns Top Marks in 2015 Corporate Equality Index Nov 24 2014
Walgreens Earns Top Marks in 2015 Corporate Equality Index Nov 24 2014
WALGREEN CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 20 2014
Cramer: Don't let skepticism run away with you Nov 19 2014
[video]Staples, Lowe's, Target Kick off AM Earnings; Jim Cramer's Pharmacy Nov 19 2014
Walgreens to Pay $1.4M for Sharing a Patient's Medical Info With Her Ex Nov 19 2014
WALGREEN CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 18 2014
[video]Shutterfly CEO: Holiday Season Is Like the ‘Super Bowl’ for Stock Nov 18 2014
Walgreens to offer affordable and needle-free blood tests in more stores (updated) Nov 18 2014
Billionaire Activist Barry Rosenstein's Highest-Conviction Stocks Nov 14 2014
Holiday shopping may not be more secure Nov 12 2014
WALGREEN CO Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Nov 12 2014
Bulls riding Walgreen momentum Nov 11 2014
Walgreens Announces Pricing of £700 Million and €750 Million Notes Offering Nov 10 2014
Walgreens Announces Pricing of £700 Million and €750 Million Notes Offering Nov 10 2014
Walgreens Hits the Rock with Court's Ruling on CFO Lawsuit Nov 10 2014
Walgreen Debuting Bonds in Europe as It Completes Boots Takeover Nov 10 2014
Walgreen Leads Busiest Week for Bond Sales in Two Months Nov 07 2014
November begins with $43bn onslaught Nov 07 2014
[$$] Walgreen Debt Sale Puts Issuance on Pace for Record Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK